Alexion: Analysts Raise Their Target Prices

Analysts’ recommendations

Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. The company develops Soliris, which has been on the market since 2007. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). However, the company has been going through tough times since its peak in 2015 due to its failed $8.4 billion acquisition of Synageva BioPharma. Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market. In this part, we’ll discuss Wall Street analysts’ recommendations and target prices for Alexion stock in the next 12 months.

Alexion: Analysts Raise Their Target Prices

As of April 12, 2018, out of the 19 analysts that were covering Alexion stock, 18 analysts gave a “buy” or “strong buy” recommendation on Alexion stock. One analyst gave a “hold” recommendation on Alexion stock, while none the analysts gave a “sell” rating on the stock.

According to analysts’ recommendations, the consensus 12-month target price for Alexion stock is $158.7. The consensus target price reflects a potential investment return of ~43.2% from an investment in Alexion stock in the next 12 months. Alexion stock closed at $110.79 on April 11, 2018.

Recent revisions and updates

On April 12, 2018, boosted by the announcement of Wilson Therapeutics acquisition by Alexion on April 11, 2018, Nomura (NMR) raised its target price on Alexion stock from $156 to $165. On April 11, 2018, Jefferies (JEF) raised its target price on Alexion Pharmaceuticals from $112 to $113.

On April 9, 2018, Raymond James (RJF) cut its target price on Alexion stock from $151 to $139.

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!